B-lineage monoclonal antibodies (anti-CD20: rituximab, ofatumumab, and obinutuzumab; anti-CD38: isatuximab and daratumumab; anti-CD30: brentuximab vedotin; anti-CD52: alemtuzumab; anti-CD269: belantamab mafodotin; or anti-CD319: elotuzumab) were used in three studies in CLL (54, 59, 66), two in MM (68, 91), and seven in NHL (110, 113, 122, 124, 127, 128, 134) as monotherapy. Here, TNFRSF17 is linked to non-Hodgkin lymphoma.